Immunic (IMUX) Share-based Compensation (2013 - 2026)

Immunic has disclosed Share-based Compensation across 14 years of filings, most recently posting $4.5 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $4.5 million, up 118.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 144.61% YoY), and the FY2025 annual result was $8.9 million, up 3.94% from the prior year.
• Share-based Compensation came in at $4.5 million for Q1 2026 at Immunic, up from $1.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $3.6 billion in Q3 2025 to a low of $1.3 million in Q4 2025.
• The 5-year median for Share-based Compensation is $4.5 million (2026), against an average of $666.5 million.
• Across the five-year window, Share-based Compensation soared 319.11% in 2022 and slumped 55.92% in 2023, its largest moves.
• Immunic's Share-based Compensation stood at $1.9 million in 2022, then fell by 13.15% to $1.6 million in 2023, then grew by 21.18% to $2.0 million in 2024, then sank by 34.11% to $1.3 million in 2025, then surged by 241.44% to $4.5 million in 2026.
• The last three Share-based Compensation figures came in at $4.5 million (Q1 2026), $1.3 million (Q4 2025), and $3.6 billion (Q3 2025), per Business Quant data.